Pharmasaga Featured by Silicon Valley Tech Media Sparknify, Spotlighting Novel Diabetes Candidate PS1

Pharmasaga is proud to announce that we have recently been featured in an in-depth report by Sparknify, a premier Silicon Valley-based tech media platform and innovation ecosystem operator. As one of the few Asian biotech startups highlighted by Sparknify, this feature marks a significant milestone in our international visibility.

Known for connecting entrepreneurs, investors, and industry leaders across AI, Deep Tech, and Healthcare, Sparknify took a deep dive into Pharmasaga's journey—from early laboratory discovery to clinical development of our first-in-class PDIA4-targeting candidate, PS1.

Key Highlights from the Coverage:

• Disease Modification Potential: While traditional diabetes management focuses primarily on blood sugar control, Pharmasaga aims to go a step further by protecting and restoring pancreatic beta-cell function, paving the way for disease reversal.

• Representing Taiwan's Biotech Innovation: The report emphasized how Taiwan's global tech narrative is expanding beyond semiconductors into world-class, original biomedical research, with Pharmasaga at the forefront of this emerging wave.

This feature follows our successful Phase 1 trial announcement on July 6, which demonstrated favorable safety, tolerability, and promising efficacy trends (HbA1c and blood glucose reduction) for PS1—setting a strong foundation for upcoming Phase 2 clinical trials.

We express our sincere gratitude to the Sparknify team for their recognition. As part of this engagement, Pharmasaga has been invited to connect directly with global venture capitalists and industry leaders at Taiwan Venture Day in Menlo Park, California, on July 23. Stay tuned for more exciting updates!